Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Alice T. Shaw(Massachusetts General Hospital), Beow Y. Yeap(Massachusetts General Hospital), Benjamin Solomon(Peter MacCallum Cancer Centre), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Justin F. Gainor(Massachusetts General Hospital), Jeffrey A. Engelman(Massachusetts General Hospital), Geoffrey I. Shapiro(Dana-Farber Cancer Institute), Daniel B. Costa(Beth Israel Deaconess Medical Center), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Mohit Butaney(Dana-Farber Cancer Institute), Ravi Salgia(University of Chicago Medical Center), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Marileila Varella‐Garcia(University of Colorado Denver), Robert C. Doebele(University of Colorado Cancer Center), Yung‐Jue Bang(Seoul National University), Kimary Kulig(Pfizer (United States)), Paulina Selaru(Pfizer (United States)), Yiyun Tang(Pfizer (United States)), Keith D. Wilner(Pfizer (United States)), Eunice L. Kwak(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), A. John Iafrate(Massachusetts General Hospital), D. Ross Camidge(University of Colorado Denver)
The Lancet Oncology
September 19, 2011
Cited by 900

Abstract


Related Papers

No related papers found

Powered by citation graph analysis